OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial
Pouessel, D, Mervoyer, A, Larrieu-Ciron, D, Cabarrou, B, Robert, M, Frenel, J, Olivier, P, Mounier, M, Cohen-Jonathan Moyal, EVolume:
21
Langue:
english
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/noz126.034
Date:
September, 2019
Fichier:
PDF, 132 KB
english, 2019